



# Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase-activating protein (FLAP) expression by glucocorticoids in monocytic cells

<sup>1</sup>M. Goppelt-Struebe, <sup>\*</sup><sup>2</sup>D. Schaefer & <sup>†</sup>A.J.R. Habenicht

<sup>\*</sup>Department of Internal Medicine IV, Nephrology Res. Unit, University of Erlangen-Nürnberg, Loschgestrasse 8, D-91054 Erlangen, Germany, Department of Internal Medicine III, University of Erlangen-Nürnberg, Krankenhausstrasse 12, D-91054 Erlangen, Germany and <sup>†</sup>Department of Internal Medicine, University of Heidelberg, Medical School, Bergheimerstrasse 58, D-69115 Heidelberg, Germany

**1** The objective of the present study was to determine the effects of dexamethasone on key constituents of prostaglandin and leukotriene biosynthesis, cyclo-oxygenase-2 (COX-2) and 5-lipoxygenase activating protein (FLAP). The human monocytic cell line THP-1 was used as a model system. mRNA and protein levels of COX-2 and FLAP were determined by Northern and Western blot analyses, respectively.

**2** Low levels of COX-2 and FLAP mRNA were expressed in undifferentiated THP-1 cells, but were induced upon differentiation of the cells along the monocytic pathway by treatment with phorbol ester (TPA, 5 nM). Maximal expression was observed after two days.

**3** Coincubation of the undifferentiated cells with dexamethasone ( $10^{-9}$ – $10^{-6}$  M) and phorbol ester prevented induction of COX-2 mRNA, but did not affect the induction of FLAP mRNA.

**4** Dexamethasone downregulated COX-2 mRNA and protein in differentiated, monocyte-like THP-1 cells. In contrast, FLAP mRNA and protein were upregulated by dexamethasone in differentiated THP-1 cells. After 24 h, FLAP mRNA levels were increased more than 2 fold. Dexamethasone did not change 5-lipoxygenase mRNA expression.

**5** Release of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and peptidoleukotrienes was determined in cell culture supernatants of differentiated THP-1 cells by ELISA. Calcium ionophore-dependent PGE<sub>2</sub> synthesis was associated with COX-2 expression, whereas COX-1 and COX-2 seemed to participate in arachidonic acid-dependent PGE<sub>2</sub> synthesis. Very low levels of peptidoleukotrienes were released from differentiated THP-1 cells upon incubation with ionophore. Treatment with dexamethasone did not significantly affect leukotriene release.

**6** These data provide evidence that prostaglandin synthesis is consistently downregulated by glucocorticoids. However, the glucocorticoid-mediated induction of FLAP may provide a mechanism to maintain leukotriene biosynthesis through more efficient transfer of arachidonic acid to the 5-lipoxygenase reaction, in spite of inhibitory effects on other enzymes of the biosynthetic pathway.

**Keywords:** Cyclo-oxygenase-2; FLAP; phospholipase A<sub>2</sub>; prostaglandin; leukotriene; glucocorticoid; monocytic cells; THP-1

## Introduction

Glucocorticoids are potent anti-inflammatory drugs because they interfere with the biosynthesis of many proinflammatory mediators in multiple cells involved in inflammatory reactions (Schleimer, 1993; Geley *et al.*, 1996). Part of their action is attributed to their interference with eicosanoid synthesis. Prostanoid biosynthesis has been investigated in considerable detail and it has been shown that glucocorticoids reduce the expression of key enzymes of prostanoid synthesis, phospholipases and cyclo-oxygenase-2 (reviewed by Goppelt-Struebe, 1997). In contrast, there is little evidence for the regulation of leukotriene biosynthesis by glucocorticoids. Treatment of various human cells with glucocorticoids differentially affected their capacity to synthesize leukotrienes, whereas prostaglandin production was reduced in all cases, indicating responsiveness of the cells. Reduced leukotriene C<sub>4</sub> (LTC<sub>4</sub>) synthesis was demonstrated in human basophils (Marone *et al.*, 1993; Hamasaki *et al.*, 1994), inhibition (Abe *et al.*, 1996) or no change (Azevedo *et al.*, 1995) was seen in macrophages whereas no change (Schleimer *et al.*, 1989), a decrease (Shindo *et al.*, 1996) or even an increase (Thomas *et al.*, 1995) was detected in human neutrophils. These conflicting results may

relate to different activation states and concomitant changes of enzyme expression of the cells investigated. Glucocorticoids bind to intracellular receptors and interfere with gene expression (Schleimer, 1993). Therefore, *de novo* protein biosynthesis appears to be a prerequisite for their action.

In the first steps of leukotriene biosynthesis, liberated arachidonic acid is transferred to 5-lipoxygenase (5-LO) by 5-lipoxygenase activating protein (FLAP) (Reid *et al.*, 1990; Mancini *et al.*, 1993; Abramovitz *et al.*, 1993). Upon activation, 5-LO translocates to the nuclear envelope where FLAP is localized (Woods *et al.*, 1993; 1995). FLAP binds free arachidonic acid, presents it to 5-LO and thus facilitates 5-LO substrate interaction. FLAP mRNA and protein expression are subject to regulation in monocytic cells (e.g. Bennett *et al.*, 1993; Flair & Pritchard, 1994) and thereby such mechanisms are involved in the regulation of leukotriene biosynthesis.

The human monocytic cell lines U937 and THP-1 provide model systems to investigate glucocorticoid effects *in vitro* (Hoff *et al.*, 1992; Abrink *et al.*, 1994). In their undifferentiated state these cell lines express no or very low levels of arachidonic acid metabolizing enzymes (Nolfo & Rankin, 1990). Upon differentiation along the monocytic lineage by treatment with phorbol ester they acquire monocyte-like properties (Schwende *et al.*, 1996). Effects of glucocorticoids on cyclo-oxygenase (COX) isozyme expression have shown that both enzymes, COX-1 and COX-2, were regulated, but the most pronounced effects were observed on the induced COX-2 ex-

<sup>1</sup> Author for correspondence at: Medizinische Klinik IV, Loschgestrasse 8, D-91054 Erlangen, Germany

<sup>2</sup> Present address: Dept. of Otorhinolaryngology, Johannes Gutenberg Universität Mainz, Langenbeckstrasse 1, D-55101 Mainz, Germany.

pression, consistent with findings in macrophages (Hoff *et al.*, 1993). THP-1 cells were chosen in the present study because they more closely approximate to mature monocytes when compared to U937 cells, also reflected by their higher levels of LTC<sub>4</sub> synthase activity (Nickolson *et al.*, 1993; Goppelt-Strube, 1995). We demonstrate here that FLAP and COX-2, key constituents of cyclo-oxygenase and 5-lipoxygenase pathways, are significantly upregulated during monocytic differentiation, but are differentially regulated by glucocorticoids.

## Methods

### Cell culture

THP-1 cells were obtained from the American Type Culture Collection (Rockville, MD, U.S.A.). The cells were grown in RPMI 1640 (Life Technologies, Eggenstein, Germany) containing 5% (v/v) foetal calf serum, 100 u ml<sup>-1</sup> penicillin, 100 µg ml<sup>-1</sup> streptomycin and 1% L-glutamine. Cells were differentiated with 5 nM 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma, München, Germany) for the times indicated.

### Northern blot analysis

Total cellular RNA was prepared by the guanidine isothiocyanate technique essentially as described by Chomczynski and Sacchi (1987). RNA (10 µg) was subjected to electrophoresis, transferred to nylon membranes and hybridized by standard techniques as described previously (Stroebel & Goppelt-Strube, 1994). Specific COX-1 and COX-2 cDNA probes were 2.767- and 1.156-kilobase EcoRI fragments from the 5'-end of mouse cDNA, respectively (DeWitt *et al.*, 1993). FLAP cDNA was kindly provided by P. Vickers, formerly at the Merck Frosst Center for Therapeutic Research in Quebec, Canada. DNA/RNA hybrids were detected by autoradiography with Kodak X-Omat AT film. Quantitative analysis was performed by densitometric scanning of the autoradiographs (Bioprofil, Fröbel, Germany). All values were corrected for differences in RNA loading by use of ethidium bromide fluorescence of 28S rRNA or hybridization with an 28S specific cDNA as indicated.

### Reversed phase polymerase chain reaction (RT-PCR)

RNA (0.3 µg) were reverse transcribed with oligo-dT primers. DNA corresponding to 0.02 µg RNA were amplified as follows: 5-LO upstream primer 5'ACC ATT GAG CAG ATC GTG GAC ACG C; downstream primer 5' GCA AGT CCT GCT CTG TGT AGA ATG GG; annealing temperature 72°C 40 cycles; FLAP upstream primer: 5' GGC CAT CGT CAC CCT CAT CAG CG, downstream primer: 5' GCC AGC AAC GGA CAT GAG GAA CAG G; annealing temperature 71°C, 24 cycles; GAPDH upstream primer 5'TCG GAG TCA ACG GAT TTG GTC GTA; downstream primer 5' ATG GAC TGT GGT CAT GAG TCC TTC; annealing temperature 66°C, 23 cycles. Amplified cDNA bands were detected by ethidium bromide staining and the volumes evaluated by densitometry. cDNA bands of 5-LO and FLAP were corrected for GAPDH expression.

### Western blot analysis

COX-2 and FLAP proteins were detected in a fraction of crude nuclear membranes. After stimulation of the cells, THP-1 cells were pelleted and resuspended in 20 mM Tris/HCl, pH 8, 10% glycerol, 10 mM EDTA, 1 mM phenylmethylsulphonylfluoride. After sonication and removal of cellular debris by low speed centrifugation (600 × g), cellular membranes were pelleted (100,000 × g) and resuspended in 20 mM Tris/HCl, pH 8. Proteins (10 µg/lane) were separated by SDS polyacrylamide gel electrophoresis and transferred to nylon membranes. A specific antibody against COX-2 was obtained from Santa Cruz Bio-

technology (Heidelberg, Germany). The antibody against FLAP was kindly provided by Dr J. Evans (Merck Frosst, Canada). Protein bands were detected with the ECL Western blotting analysis system from Amersham (Braunschweig, Germany).

### Determination of PGE<sub>2</sub> and peptidoleukotrienes

PGE<sub>2</sub> and peptidoleukotrienes (pLT) were determined in cell culture supernatants essentially as described previously (Schaefer *et al.*, 1996). Release was determined in 4 independent experiments with triplicate biological samples each assayed in duplicate. The antibody directed against pLT recognized LTC<sub>4</sub> and the metabolites LTD<sub>4</sub> and LTE<sub>4</sub> with equal sensitivity (Reinke *et al.*, 1991). Crossreactivity for arachidonic acid was tested between 10<sup>-8</sup> and 10<sup>-4</sup> M arachidonic acid. Antibodies crossreacted with 10<sup>-4</sup> M arachidonic acid, but not with concentrations of 10<sup>-5</sup> M and below. Detection limit was 3 pg/well (30 pg ml<sup>-1</sup>) for pLT and PGE<sub>2</sub>.

### Statistical analysis

Statistical significance was calculated by the non-paired two-tailed Student's *t* test. A *P* value <0.05 was considered to indicate a statistically significant difference between two sets of data.


## Results

### Expression of FLAP and COX-2 during monocytic differentiation

Low levels of FLAP mRNA expression were detectable in undifferentiated THP-1 cells. Upon differentiation with low concentrations of phorbol ester (5 nM TPA), FLAP mRNA expression was induced, maximal expression being observed between 24 to 40 h (Figure 1). Concomitant incubation of THP-1 cells with TPA and dexamethasone (10<sup>-6</sup> M) did not change the time course or intensity of FLAP mRNA expression (Figures 1 and 2). Of the cyclo-oxygenase isoenzymes, only COX-2 mRNA was significantly induced upon differentiation. Dexamethasone interfered with COX-2 mRNA induction at concentrations as low as 10<sup>-9</sup> M (Figure 2).

### Effect of dexamethasone on FLAP expression in differentiated THP-1 cells

Undifferentiated THP-1 cells represent rather immature monocytic cells. Upon incubation with phorbol ester, these cells become more monocyte-like. Therefore, the effect of dexamethasone on FLAP and COX-2 expression was also investigated in THP-1 cells that had been differentiated with TPA (5 nM) for 40 h. When differentiated THP-1 cells were treated with fresh medium, they showed a further increase in FLAP mRNA expression (163 ± 9% after 24 h, with TPA-differentiated cells set to 100%, *n* = 4). Levels remained elevated for at least 48 h (Figure 3). Treatment of differentiated



**Figure 1** Upregulation of FLAP during monocytic differentiation. Undifferentiated THP-1 cells were incubated with TPA (5 nM) and/or dexamethasone (Dex, 10<sup>-6</sup> M) for the times indicated. Northern blot analysis with specific cDNAs for FLAP and 18 S rRNA was performed as described in Methods. The blot is representative of 3 independent experiments with similar results.

THP-1 cells with dexamethasone ( $10^{-6}$  M) increased FLAP expression ( $258 \pm 62\%$  within 24 h,  $n=4$ ,  $P<0.05$  compared to medium-treated cells). Enhancement was concentration-dependent with  $10^{-8}$  M dexamethasone being effective (Figure 4). COX-2 expression, in contrast, was downregulated by dexamethasone within the first hours of incubation. COX-1 expression was very low in these cells and not significantly affected by either TPA or dexamethasone.


Expression of 5-LO mRNA was not detectable by Northern blot analysis. Therefore, reverse transcriptase-polymerase chain reaction (RT-PCR) was performed (Janssen-Timmen *et al.*, 1995). Dexamethasone did not significantly affect the expression of 5-LO mRNA, whereas FLAP mRNA expression was elevated (data not shown). The latter result was comparable with the results obtained by Northern blot analysis.

#### Differential regulation of COX-2 and FLAP at the protein level


The changes in FLAP and COX-2 mRNA expression were also observed at the protein level (Figure 5): upon differentiation with TPA, FLAP and COX-2 protein were increased in the nuclear membrane fraction. Further treatment of differentiated cells with dexamethasone for 24 h caused COX-2 protein to decrease but FLAP protein to increase (Figure 5).

#### Effect of dexamethasone on eicosanoid release


In order to detect changes at the product level, differentiated THP-1 cells were incubated with medium alone or with medium supplemented with dexamethasone ( $10^{-6}$  M). Cells were




**Figure 2** Interference by dexamethasone of COX-2 induction at low concentrations. Undifferentiated THP-1 cells (Co) were incubated with TPA (5 nM) and dexamethasone ( $10^{-6}$ – $10^{-9}$  M) for 24 h. Thereafter, RNA was extracted and Northern blot analysis performed as described in Methods.




**Figure 3** Effect of dexamethasone on gene expression in TPA-differentiated THP-1 cells. Undifferentiated THP-1 cells (Co) were differentiated with TPA for 40 h. They were further incubated with fresh medium in the presence (+) or absence (–) of dexamethasone (Dex,  $10^{-6}$  M) for the times (h) indicated. RNA was extracted and Northern blot analysis was performed as described in Methods. The autoradiogram is representative of 3 experiments with similar results.



**Figure 4** Concentration-dependent induction of FLAP mRNA by dexamethasone in differentiated THP-1 cells. THP-1 cells (Co) were differentiated with TPA for 40 h. They were further incubated with fresh medium in the presence or absence of dexamethasone ( $10^{-6}$ – $10^{-10}$  M) for 24 h. Data shown are a Northern blot hybridization with a cDNA specific for FLAP and the ethidium bromide fluorescence of the 28S rRNA.



**Figure 5** Differential modulation of COX-2 and FLAP protein expression in differentiated THP-1 cells. THP-1 cells (Co) were differentiated with TPA for the times indicated. Dexamethasone ( $10^{-6}$  and  $10^{-7}$  M) was added between 40 and 64 h. Crude membrane preparations containing nuclear membranes were fractionated by SDS polyacrylamide gel electrophoresis. COX-2 and FLAP proteins were detected by specific antibodies.



**Figure 6** Release of PGE<sub>2</sub> from differentiated THP-1 cells. THP-1 cells were differentiated with TPA for 40 h. They were further incubated with fresh medium in the presence (hatched columns) or absence (open columns) of dexamethasone ( $10^{-6}$  M) for 24 h. Cells were left untreated (Co) or stimulated with ionophore A23187 (A23;  $10 \mu\text{g ml}^{-1}$ ) or arachidonic acid (AA;  $10 \mu\text{M}$ ) for 30 min. PGE<sub>2</sub> was determined in the cellular supernatants by ELISA. Data are means  $\pm$  s.d. of 4 independent experiments.

then stimulated for 30 min with ionophore A23187 ( $10 \mu\text{g ml}^{-1}$ ), to activate endogenous synthesis of eicosanoids, or with exogenous arachidonic acid ( $10^{-5} \text{ M}$ ). Stimulation with ionophore increased  $\text{PGE}_2$  synthesis about 3 fold (Figure 6).  $\text{PGE}_2$  levels of dexamethasone-treated cells fell below basal levels of unstimulated cells ( $58.8 \pm 10.4\%$  of basal levels;  $n = 4$ ,  $P < 0.001$  in each experiment). With exogenous arachidonic acid as substrate, large amounts of  $\text{PGE}_2$  were formed ( $> 6 \text{ ng ml}^{-1}$ ). In contrast to the ionophore-stimulated  $\text{PGE}_2$  synthesis, arachidonic acid-stimulated  $\text{PGE}_2$  synthesis was only partially inhibited in dexamethasone-treated cells ( $34.0 \pm 4.5\%$  of arachidonic acid-stimulated  $\text{PGE}_2$  release,  $n = 3$ ).

Comparatively low but significant levels of peptidoleukotrienes (pLT) were identified in the supernatants of differentiated THP-1 cells. Basal levels were close to the detection limit of about  $30 \text{ ng ml}^{-1}$  ( $103 \pm 56 \text{ pg ml}^{-1}$ , 4 independent experiments with triplicate samples). Increased levels of pLT were found when differentiated THP-1 cells were treated with ionophore A23187 ( $10 \mu\text{g ml}^{-1}$ ), but did not reach statistical significance ( $121 \pm 7\%$ , compared to basal levels,  $n = 3$ ). Incubation of differentiated THP-1 cells with dexamethasone for 24 h before treatment did not significantly alter the amount of stimulated pLT released.

## Discussion

Inhibition of prostanoid synthesis in monocytic cells is considered to be part of the anti-inflammatory potency of glucocorticoids. A strong effect of the glucocorticoid dexamethasone was also observed in the cellular system investigated, the human monocytic cell line THP-1. When undifferentiated cells were differentiated along the monocytic pathway by treatment with phorbol ester, concomitant treatment with dexamethasone completely prevented induction of COX-2 mRNA and protein, whereas the low levels of COX-1 expression were not significantly altered. Induction of COX-1 as described in Smith *et al.* (1993) was not detected by us in previous experiments (Hoff *et al.*, 1994) and was not seen in the present experiments. The reason for this discrepancy is unclear at present. However, results are consistent with data obtained previously showing that COX-2 is a major target of glucocorticoid action in monocytic cells (Fu *et al.*, 1990; Hoff *et al.*, 1993).

The functional activity of 5-LO, the enzyme catalyzing the first step in leukotriene synthesis from arachidonic acid, critically depends on the 5-lipoxygenase activating protein, FLAP. FLAP was first considered to act as a docking protein, directing the cytosolic 5-LO towards cellular membranes, primarily nuclear membranes (Ford-Hutchinson, 1991; Woods *et al.*, 1995). However, current evidence suggests that FLAP acts as an arachidonic acid binding protein presenting arachidonic acid to 5-LO (Abramovitz *et al.*, 1993; Mancini *et al.*, 1993). Expression of FLAP was shown in a variety of cells to correlate well with their capacity to synthesize leukotrienes (Reid *et al.*, 1990). In undifferentiated THP-1 cells, we found very low levels of FLAP mRNA expression in accordance with previous results showing that undifferentiated THP-1 cells were unable to form leukotrienes (Nolfo & Rankin, 1990). However, upon differentiation with TPA FLAP mRNA expression was strongly increased. Induction was transient with a decrease visible after 72 h. Also *in vivo*, monocyte differentiation seems to involve an increase in FLAP expression as shown for the maturation of monocytes to alveolar macrophages (Coffey *et al.*, 1994).

Coincubation of THP-1 cells with dexamethasone together with TPA did not affect FLAP mRNA induction. In contrast, differentiated THP-1 cells were sensitive to dexamethasone: dexamethasone increased both mRNA and protein expression of FLAP in differentiated THP-1 cells. We have shown previously that the number of glucocorticoid receptors is upre-

gulated during monocytic differentiation of U937 cells (Koehler *et al.*, 1990). Higher numbers of receptors may be necessary to mediate the effect of dexamethasone on FLAP expression than on COX-2 expression. In line with this argument, COX-2 expression was sensitive to glucocorticoid action in undifferentiated THP-1 cells and much lower concentrations of dexamethasone were needed to inhibit COX-2 expression than FLAP expression in differentiated cells. Depending on the gene and the cellular system, glucocorticoids may affect transcriptional as well as posttranscriptional mechanisms (Goppelt-Strube, 1997). In human neutrophils a direct upregulation of FLAP mRNA by dexamethasone was observed (Pouliot *et al.*, 1994). The molecular mechanism of dexamethasone action in THP-1 cells was not investigated, but it is tempting to speculate that glucocorticoid receptors directly interfere with the glucocorticoid responsive element located in the promoter region of the FLAP gene (Kennedy *et al.*, 1991).

Inhibition of COX-2 by dexamethasone was clearly reflected at the product level. Ionophore-induced  $\text{PGE}_2$  synthesis was almost completely inhibited in cells treated with dexamethasone. When the cells were incubated with high concentrations of exogenous arachidonic acid to assay for  $\text{PGE}_2$  synthesis independent of phospholipases, inhibition by dexamethasone was not complete suggesting that under these conditions, COX-1 may also contribute to the high  $\text{PGE}_2$  synthesis rate.

Undifferentiated THP-1 cells were shown to be unable to form any products of the 5-lipoxygenase pathway (Nolfo & Rankin, 1990) and even differentiated THP-1 cells released very low concentrations of pLTs upon stimulation. However, induction of FLAP by dexamethasone did not significantly change pLT release. This may be due to the counteracting effects of dexamethasone on activity and/or expression of phospholipases  $\text{A}_2$ . In differentiated THP-1 cells, we observed reduced mRNA levels of the cytosolic phospholipase  $\text{A}_2$  (cPLA<sub>2</sub>) after dexamethasone treatment (unpublished observation) in line with reduced phospholipase activity determined previously in glucocorticoid-treated differentiated U937 cells (Koehler *et al.*, 1989). Additional effects of glucocorticoids on the activation of cPLA<sub>2</sub> were reported in macrophages and may also play a role in monocytic cells (Gewert & Sundler, 1995). It is not known yet which type of phospholipase  $\text{A}_2$  is responsible for the liberation of arachidonic acid for leukotriene synthesis in THP-1 cells. In a recent paper, Marshall *et al.* (1997) provided evidence that not cPLA<sub>2</sub> but a low molecular weight PLA<sub>2</sub> may provide arachidonic acid for leukotriene synthesis in human monocytes. Expression of this type of PLA<sub>2</sub> has also been shown to be inhibited by glucocorticoids (Nakano *et al.*, 1990; Vervoordeldonk *et al.*, 1996). Our data are thus in line with the interpretation that inhibition of phospholipase activity opposes induction of FLAP, leading to an inhibition of pLT synthesis in some experiments and a stimulation in others. The situation may be further complicated by glucocorticoid effects on LTC<sub>4</sub> synthase, an enzyme that is regulated by phosphorylation (Ali *et al.*, 1994). Partial inhibition of LTC<sub>4</sub> synthase was observed in basophilic leukemia cells (Hamasaki *et al.*, 1994), while the regulation of this enzyme by glucocorticoids in monocytic cells is unknown.

Taken together our data indicate that glucocorticoids induce FLAP expression that should result in an increased leukotriene production, but seems to be counterbalanced by glucocorticoid effects on other enzymes in the biosynthetic pathway. These data may help to explain the varying effects of glucocorticoids on leukotriene synthesis observed *ex vivo*.

This work was supported by the Deutsche Forschungsgemeinschaft (Ste-196/3-2 TP1 to MGS). The expert technical assistance of M. Rehm, M.M. Hembera and M. Hildner is gratefully acknowledged.

## References

- ABE, M., GOYA, T., MITSUYAMA, T., TORISU, M. & FURUKAWA, T. (1996). Evaluation of the effects of steroids on experimental septic lung injury. *Prostaglandins Leukotrienes Essent. Fatty Acids*, **54**, 123–128.
- ABRAMOVITZ, M., WONG, E., COX, M.E., RICHARDSON, C.D., LI, C. & VICKERS, P.J. (1993). 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. *Eur. J. Biochem.*, **215**, 105–111.
- ABRINK, M., GOBEL, A.E., HUANG, R.N. & HELLMAN, L. (1994). Human cell lines U937, THP-1 and Mono Mac 6 represent relatively immature cells of the monocyte-macrophage cell lineage. *Leukemia*, **8**, 1579–1584.
- ALI, A., FORD-HUTCHINSON, A.W. & NICHOLSON, D.W. (1994). Activation of protein kinase C down-regulates leukotriene C4 synthase activity and attenuates cysteinyl leukotriene production in an eosinophilic substrain of HL-60 cells. *J. Immunol.*, **153**, 776–788.
- AZEVEDO, I., DEBLIC, J., SCHEINMANN, P., VARGAFTIG, B.B. & BACHELET, M. (1995). Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Modulation by dexamethasone. *Am. J. Respir. Crit. Care Med.*, **152**, 1208–1214.
- BENNETT, C.F., CHIANG, M.-Y., MONIA, B.P. & CROOKE, S.T. (1993). Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. *Biochem. J.*, **289**, 33–39.
- CHOMCZYNSKI, P. & SACCHI, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.*, **162**, 156–159.
- COFFEY, M., WILCOXEN, S. & PETERS-GOLDEN, M. (1994). Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism which accompanies differentiation of peripheral blood monocytes into alveolar macrophages. *Am. J. Respir. Cell. Mol. Biol.*, **11**, 153–158.
- DEWITT, D.L., MEADE, E.A. & SMITH, W.L. (1993). PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. *Am. J. Med.*, **95**, 40S–44S.
- FLAIR, A. & PRITCHARD, K.A. (1994). Oxidized low density lipoprotein increases U937 cell 5-lipoxygenase activity: induction of 5-lipoxygenase activating protein. *Biochem. Biophys. Res. Commun.*, **201**, 1014–1020.
- FORD-HUTCHINSON, A. (1991). FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. *Trends Pharmacol. Sci.*, **12**, 68–70.
- FU, J.Y., MASFERRER, J.L., SEIBERT, K., RAZ, A. & NEEDLEMAN, P. (1990). The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. *J. Biol. Chem.*, **265**, 16737–16740.
- GELEY, S., FIEGL, M., HARTMANN, B.L. & KOFLER, R. (1996). Genes mediating glucocorticoid effects and mechanisms of their regulation. *Rev. Physiol. Biochem. Pharmacol.*, **128**, 1–97.
- GEWERT, K. & SUNDLER, R. (1995). Dexamethasone down-regulates the 85 kDa phospholipase A2 in mouse macrophages and suppresses its activation. *Biochem. J.*, **307**, 499–504.
- GOPPELT-STRUEBE, M. (1995). Two step purification of human and murine leukotriene C4 synthase. *Biochim. Biophys. Acta*, **1256**, 257–261.
- GOPPELT-STRUEBE, M. (1997). Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. *Biochem. Pharmacol.*, **53**, 1389–1395.
- HAMASAKI, Y., ABE, M., MATSUMOTO, S., ICHIMANY, T., KOBAYASHI, I., TANAKA, E., MATSUO, M., HARA, N. & MIYAZAKI, S. (1994). Inhibition by dexamethasone of retinoid acid-induced enhancement of leukotriene C4 synthesis in rat basophilic leukemia-1 cells. *Am. J. Respir. Cell. Mol. Biol.*, **11**, 49–56.
- HOFF, T., DEWITT, D., KAEVER, V., RESCH, K. & GOPPELT-STRUEBE, M. (1993). Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells. *FEBS Lett.*, **320**, 38–42.
- HOFF, T., KAEVER, V., RESCH, K., DEWITT, D.L. & GOPPELT-STRUEBE, M. (1994). Prostaglandin endoperoxide synthase-1 and synthase-2 expression in differentiating human monocytic cells. *Agents Actions*, **41**, C159–C161.
- HOFF, T., SPENCKER, T., EMMENDOERFFER, A. & GOPPELT-STRUEBE, M. (1992). Effects of glucocorticoids on the TPA-induced monocytic differentiation. *J. Leukocyte Biol.*, **52**, 173–182.
- JANSSEN-TIMMEN, U., VICKERS, P., WITTIG, U., LEHMANN, W.D., STARK, H.-J., FUSENIG, N.E., ROSENBAUGH, T., RADMARK, O., SAMUELSSON, B. & HABENICHT, A.J.R. (1995). Expression of 5-lipoxygenase in differentiating human skin keratinocytes. *Proc. Natl. Acad. Sci. U.S.A.*, **92**, 6966–6970.
- KENNEDY, B.P., DIEHL, R.E., BOIE, Y., ADAM, M. & DIXON, R.A.F. (1991). Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). *J. Biol. Chem.*, **266**, 8511–8516.
- KOEHLER, L., HASS, R., DEWITT, D.L., RESCH, K. & GOPPELT-STRUEBE, M. (1990). Glucocorticoid-induced reduction of prostanoid synthesis in TPA-differentiated U937 cells is mainly due to a reduced cyclooxygenase activity. *Biochem. Pharmacol.*, **40**, 1307–1316.
- KOEHLER, L., HASS, R., GOPPELT-STRUEBE, M., KAEVER, V. & RESCH, K. (1989). Differential effect of dexamethasone on the regulation of phospholipase A2 and prostanoid synthesis in undifferentiated and phorbol-ester-differentiated U937 cells. *J. Cell. Biochem.*, **40**, 397–406.
- MANCINI, J.A., ABRAMOVITZ, M., COX, M.E., WONG, E., CHARLESON, S., PERRIER, H., WANG, Z., PRASIT, P. & VICKERS, P.J. (1993). 5-Lipoxygenase-activating protein is an arachidonate binding protein. *FEBS Lett.*, **318**, 277–281.
- MARONE, G., STELLATO, C., RENDA, A. & GENOVESE, A. (1993). Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils. *Eur. J. Clin. Pharmacol.*, **45**, 17–20.
- MARSHALL, L.A., BOLOGNESE, B., WINKLER, J.D. & ROSHAK, A. (1997). Depletion of human monocyte 85-kDa phospholipase A2 does not alter leukotriene formation. *J. Biol. Chem.*, **272**, 759–765.
- NAKANO, T., OHARA, O., TERAOKA, H. & ARITA, H. (1990). Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. *J. Biol. Chem.*, **265**, 12745–12748.
- NICKOLSON, D.W., ALI, A., VAILLANCOURT, J.P., CALAYCAY, J.R., MUMFORD, R.A., ZAMBONI, R.J. & FORD-HUTCHINSON, A.W. (1993). Purification to homogeneity and the N-terminal sequence of human leukotriene C4 synthase: A homodimeric glutathione S-transferase composed of 18 kDa subunits. *Proc. Natl. Acad. Sci. U.S.A.*, **90**, 2015–2019.
- NOLFO, R. & RANKIN, J.A. (1990). U937 and THP-1 cells do not release LTB4, LTC4, or LTD4 in response to A23187. *Prostaglandins*, **39**, 157–165.
- POULIOT, M., MCDONALD, P.P., BORGEAT, P. & MCCOLL, S.R. (1994). Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils. *J. Exp. Med.*, **179**, 1225–1232.
- REID, G.K., KARGMAN, S., VICKERS, P.J., MANCINI, J.A., LEVEILLE, C., ETHIER, D., MILLER, D.K., GILLARD, J.W., DIXON, R.A.F. & EVANS, J.F. (1990). Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. *J. Biol. Chem.*, **265**, 19818–19823.
- REINKE, M., HOPPE, U., RÖDER, T., BESTMANN, H.-J., MOLLENHAUER, J. & BRUNE, K. (1991). A monoclonal antibody against the sulfidopeptide leukotrienes LTC4, LTD4 and LTE4. *Biochim. Biophys. Acta*, **1081**, 274–278.
- SCHAEFER, D., LINDENTHAL, U., WAGNER, M., BÖLCSKEI, P.L. & BAENKLER, H.W. (1996). Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. *Thorax*, **51**, 919–923.
- SCHLEIMER, R.P. (1993). An overview of glucocorticoid anti-inflammatory actions. *Eur. J. Clin. Pharmacol.*, **45**, S3–S7.
- SCHLEIMER, R.P., FREELAND, H.S., PETERS, S.P., BROWN, K.E. & DERSE, C.P. (1989). An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. *J. Pharmacol. Exp. Ther.*, **250**, 598–605.
- SCHWENDE, H., FITZKE, E., AMBS, P. & DIETER, P. (1996). Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. *J. Leukocyte Biol.*, **59**, 555–561.
- SHINDO, K., KOIDE, K., FUKUMURA, M. & HIRAI, Y. (1996). In vivo effect of prednisolone on release of leukotriene B4 from neutrophils from asthmatic patients. *Biochem. Biophys. Res. Commun.*, **222**, 759–763.

- SMITH, C.J., MORROW, J.D., ROBERTS, II, L.J. & MARNETT, L.J. (1993). Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1). *Biochem. Biophys. Res. Commun.*, **192**, 787–793.
- STROEBEL, M. & GOPPELT-STRUEBE, M. (1994). Signal transduction pathways responsible for serotonin-mediated prostaglandin G/H synthase expression in rat mesangial cells. *J. Biol. Chem.*, **269**, 22952–22957.
- THOMAS, E., LEROUX, J.L., BLOTMAN, F., DESCOMPS, B. & CHAVIS, C. (1995). Enhancement of leukotriene A4 biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose. *Biochem. Pharmacol.*, **49**, 243–248.
- VERVOORDELDONK, M.J.B.M., SCHALKWIJK, C.G., PFEILSCHIFTER, J. & VAN DEN BOSCH, H. (1996). Effects of dexamethasone and transforming growth factor-2 on group II phospholipase A2 mRNA and activity levels in interleukin 1- and forskolin-stimulated mesangial cells. *Biochem. J.*, **315**, 435–441.
- WOODS, J.W., COFFEY, M.J., BROCK, T.G., SINGER, I.I. & PETERS-GOLDEN, M. (1995). 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. *J. Clin. Invest.*, **95**, 2035–2046.
- WOODS, J.W., EVANS, J.F., ETHIER, D., SCOTT, S., VICKERS, P.J., HEARN, L., HEILBEIN, J.A., CHARLESON, S. & SINGLER, I.I. (1993). 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. *J. Exp. Med.*, **178**, 1935–1946.

(Received April 4, 1997

Revised June 13, 1997

Accepted July 9, 1997)